AdAlta Ltd has released an oral presentation and poster delivered at the International Society for Cell & Gene Therapy ANZ 2026 Regional Conference held in Melbourne.

AdAlta’s presentation and poster describes how its “East to West” business model brings promising Asian cell therapies to Western patients in a de-risked, capital efficient manner. They feature AdAlta’s collaboration with Shanghai Cell Therapy Group on lead product BZDS1901 (now known by AdAlta product code EW 001), a ground breaking CAR-T cell therapy that has demonstrated hard to achieve complete responses in advanced mesothelioma, a deadly cancer asspciated with asbestos expsoure. It also describes manufacturing collaborations with Cell Therapies Pty Ltd and Oribiotech that aim to deliver scalable, lower-cost CAR-T manufacturing across the Asia-Pacific.